Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)
Sponsor: Ionis Pharmaceuticals, Inc.
Terminated
Sponsor decision to terminate study early. Decision not based on safety concerns.
Other terminated trials from Ionis Pharmaceuticals, Inc.
- Amyloidosis · Dec 2023
- Beta Thalassemia Intermedia · Phase PHASE2 · Mar 2023
- Chronic Bronchitis · Phase PHASE2 · Aug 2021
- Type 2 Diabetes · Phase PHASE2 · Mar 2014
- Type 2 Diabetes Mellitus · Phase PHASE2 · Mar 2007
More terminations from Ionis Pharmaceuticals, Inc.
A PHASE1 clinical study on Alzheimer Disease and Down Syndrome, this trial is terminated or withdrawn. The trial is conducted by Ionis Pharmaceuticals, Inc. and has accumulated 8 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Oct 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ionis Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .